# Quality Control/Quality Assurance Reviews for CTSA Submissions

> **NIH NIH UL1** · UNIVERSITY OF KANSAS MEDICAL CENTER · 2020 · $147,168

## Abstract

OVERALL UL1: ABSTRACT Frontiers: University of Kansas Clinical and Translational Science Institute has
been a catalyst for bringing together translational science investigators and stakeholders across the KC region,
and beyond. Located at KUMC under the leadership of Mario Castro, MD, MPH, our commitment to team
science and multidisciplinary collaboration reaches beyond the walls of our academic health science center
and promotes collaboration among investigators from diverse disciplines across local partner academic
institutions and affiliated health care institutions (Children’s Mercy Kansas City, University of Missouri-Kansas
City, Saint Luke’s Health System, The University of Kansas Health System, Kansas City University of Medicine
and Biosciences, and Kansas State University). The vision of Frontiers is to contribute to and lead national
efforts to transform the way we do clinical and translational research (CTR), and to ensure research is more
rapidly and more efficiently translated to the point of care so that it may contribute to improved health.
Specifically, Frontiers aims to: 1) Engage in bi-directional collaboration with all stakeholders to develop,
demonstrate, and disseminate advances across the translational science spectrum that insures inclusion and
integration of complex and diverse populations and individuals across the lifespan from birth to end of life; 2)
Create a sustainable translational workforce of multi-disciplinary investigators, research personnel, and
community and patient stakeholders in the use of translational science tools through innovative and creative
programs; and 3) Strengthen institutional and regional infrastructure to accelerate translational research. We
will accomplish these aims by drawing on our considerable strengths: a) developing informatics tools for
making EHR data ‘research ready’ and implementing clinic- and community-based registries for study
recruitment and other translational research applications; b) nurturing and sustaining strong patient and
community engagement relationships that will support research with African American, Latino, American
Indian, LGBTQ, pediatric, geriatric, rare disease, prison, and rural populations; c) offering innovative training
programs for the entire CTR workforce (not just investigators), including plans for comprehensive
entrepreneurship and implementation research training and creating new team science brainstorming
mechanisms that will lead to multidisciplinary discovery projects and d) advancing medical devices and re-
purposed drugs to patients through novel strategies developed by Frontiers’ Institute for Advancing Medical
Innovations that is nationally known for its product development translational research and high impact
collaborations with industry, academia, government, and disease philanthropy partners. All Frontiers units are
linked by a group of Navigators that can be accessed by Frontiers investigative teams and community
partners. These plans ...

## Key facts

- **NIH application ID:** 10159055
- **Project number:** 3UL1TR002366-04S2
- **Recipient organization:** UNIVERSITY OF KANSAS MEDICAL CENTER
- **Principal Investigator:** Mario Castro
- **Activity code:** UL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $147,168
- **Award type:** 3
- **Project period:** 2017-09-07 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10159055

## Citation

> US National Institutes of Health, RePORTER application 10159055, Quality Control/Quality Assurance Reviews for CTSA Submissions (3UL1TR002366-04S2). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10159055. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*